JAK/TYK2
KenWarringtonMD MdWarrington
4 years 11 months ago
This convinces me! #TNF inhibitors vs #JAKI
great debate at #ACR20 https://t.co/Xb8KkmDJ8f
Dr. Antoni Chan synovialjoints
4 years 11 months ago
New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
Leonard Calabrese LCalabreseDO
4 years 11 months ago
Important study helping dissect the JAK-IFN axis I believe - we need to be cautious in attacking this axis as anifrolumab has >2x Zoster of JAKi's- we need to read the tea leaves from IEIs and COVID-19 #ACR20 @JYazdanyMD @Lupusdoc @casanova_lab @cannalab1 https://t.co/scI13jwFZd
Treatment Options for Psoriatic Arthritis: Dr Robert Chao
Dr. Robert Chao discusses abstracts #0375 and #0381 as presented Friday at the ACR 2020 annual meeting.
Eric Dein ejdein1
4 years 11 months ago
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
Eric Dein ejdein1
4 years 11 months ago
The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht
Eric Dein ejdein1
4 years 11 months ago
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
Robert B Chao, MD doctorRBC
4 years 11 months ago
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest
k dao KDAO2011
4 years 11 months ago
#GREATDEBATE Dr. Weinblatt won - but based on the limited # people polled d/t difficulties with website #ACR20 @RheumNow
Spondyloarthritis at ACR 2020: Dr. Lianne Gensler
San Francisco-based rheumatologist Dr. Lianne Gensler examines a wide range of spondyloarthritis topics at ACR 2020, including how to join up with others interested in spondyloarthritis; enthesitis; the utility of MRI for the diagnosis for axSpA; novel treatments; and the impact of drugs on disease modification.
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
Dr. Vibeke Strand discusses opening day at ACR 2020, sessions she's looking forward, and provides a sneak peek into The Great Debate.
Peter Nash drpnash
4 years 11 months ago
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
Peter Nash drpnash
4 years 11 months ago
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
Poster Hall